Design principles for clinical efficacy of cancer nanomedicine: a look into the basics.

Design principles for clinical efficacy of cancer nanomedicine: a look into the basics.
复制标题

DOI:
10.1021/nn4015399
复制
发表时间:
2013-04-23
期刊:
影响因子:
17.1
通讯作者:
Kulkarni, Ashish
Kulkarni, Ashish
中科院分区:
材料科学1区
文献类型:
--
作者:
Sengupta, Shiladitya;Kulkarni, Ashish

文献摘要

参考文献

被引文献

相似文献

随着癌症纳米医学的发展,人们对临床翻译的期望越来越高。然而,定义临床成功的纳米药物的参数是什么,这将通过增加疗效来衡量,而不仅仅是传递的容易或毒性的降低?这一观点建立在Stefan ick等人的一项基础研究的基础上,该研究涉及正确的设计原则在纳米药物工程中的重要性,例如多肽-聚乙二醇-连接物的长度和配体密度在细胞对脂质体纳米颗粒的摄取中的重要性。该观点阐述了其他设计参数,这些参数可能有助于临床翻译,以及对肿瘤生物学的新见解将如何激励下一代癌症纳米医学。摘要:随着我们迅速将癌症纳米药物推向临床,哪些基本设计参数将影响结果?我们可以从抗体-药物结合物中学到什么,以促进纳米药物通过“疗效测试”?这一观点解决了其中一些问题。
With the advances in cancer nanomedicine, there is an increasing expectation for clinical translation. However, what are the parameters of a nanomedicine that will define clinical success, which will be measured by increased efficacy and not just ease of delivery or reduction in toxicity? This perspective builds on a fundamental study by Stefanick et al on the significance of the right design principles in the engineering of a nanomedicine, such as peptide-PEG-linker length and ligand density in cellular uptake of liposomal nanoparticles. The perspective addresses additional design parameters that can potentially facilitate clinical translation as well as how emerging insights into tumor biology will inspire the next generation cancer nanomedicines. SUMMARY: As we rapidly race cancer nanomedicines towards the clinics, what are the fundamental design parameters that will influence outcome? What can we learn from antibody-drug conjugates that will facilitate nanomedicines passing the 'efficacy test'? This perspective addresses some of these questions.
DOI: 10.1038/nrd3958
发表时间: 2013-03
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
通讯作者: --
DOI: 10.1158/1078-0432.ccr-11-1417
发表时间: 2011-10-15
影响因子: 11.5
作者:
Teicher, Beverly A.;Chari, Ravi V. J.
通讯作者: Chari, Ravi V. J.
DOI: 10.1016/j.addr.2012.09.038
发表时间: 2013-01
影响因子: 16.1
作者:
Venditto, Vincent J.;Szoka, Francis C., Jr.
通讯作者: Szoka, Francis C., Jr.
DOI: 10.1016/j.ccr.2009.10.013
发表时间: 2009-12-08
期刊: Cancer cell
影响因子: 50.3
作者:
Sugahara KN;Teesalu T;Karmali PP;Kotamraju VR;Agemy L;Girard OM;Hanahan D;Mattrey RF;Ruoslahti E
通讯作者: Ruoslahti E